albiomin 20% (▼) 200 g/1 l otopina za infuziju
medis international d.o.o. sarajevo - albumin - otopina za infuziju - 200 g/1 l - 1 l otopine za infuziju sadrži: 200 g humanog plazma proteina koji sadrži najmanje 96% albumina
albiomin 5% (▼) 50 g/1 l otopina za infuziju
medis international d.o.o. sarajevo - albumin - otopina za infuziju - 50 g/1 l - 1 l otopine za infuziju sadrži ; 50 g humanog plazma proteina koji sadrži najmanje 96 % albumina
albutein 50 g/l 50 mg/1 ml rastvor za infuziju
amicus pharma d.o.o. - albumin - rastvor za infuziju - 50 mg/1 ml - 1 ml rastvora za infuziju sadrži: 50 mg albumina, humanog
albutein 50 g/l 50 mg/1 ml rastvor za infuziju
amicus pharma d.o.o. - albumin - rastvor za infuziju - 50 mg/1 ml - 1 ml rastvora za infuziju sadrži: 50 mg albumina, humanog
albutein 50 g/l 50 mg/1 ml rastvor za infuziju
amicus pharma d.o.o. - albumin - rastvor za infuziju - 50 mg/1 ml - 1 ml rastvora za infuziju sadrži: 50 mg albumina, humanog
albutein 200 g/l 200 mg/1 ml rastvor za infuziju
amicus pharma d.o.o. - albumin - rastvor za infuziju - 200 mg/1 ml - 1 ml rastvora za infuziju sadrži: 200 mg albumina, humanog
albutein 200 g/l 200 mg/1 ml rastvor za infuziju
amicus pharma d.o.o. - albumin - rastvor za infuziju - 200 mg/1 ml - 1 ml rastvora za infuziju sadrži: 200 mg albumina, humanog
deltyba
otsuka novel products gmbh - Деламанид - tuberkuloza, višestruko otporna - antimikobakterija - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 i 5. treba uzeti u obzir formalne preporuke za odgovarajuće korištenje antibakterijskih posrednika.
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastična sredstva - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukemije, dlakave stanice - antineoplastična sredstva - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).